Previous studies have shown that m6A-RNA methylation plays an important role in the development of NSCLC, and its methylation-related factors can act as oncogenes (e.g., ALKBH5) or anti-oncogenes (e.g., METTL3, FTO, YTHDF1, HNRNPA2B1, HNRNPC and eIF3, etc.)which play roles in NSCLC cell proliferation, migration, invasion, apoptosis and cell cycle, and may be potential new targets for NSCLC therapy. The gene discussed is FTO; the disease is non-small cell lung carcinoma.